Cytosorbents Corporation (CTSO:NASDAQ) closed at $5.27 on October 23, 2026, down 12.31% on the day. The stock trades 69.4% below its 52-week high of $17.20 and 85.6% above its 52-week low of $2.84. Cytosorbents Corporation is part of the Health Care sector (Medical/Dental Instruments).
In 251 trading sessions since October 23, 2025, CTSO closed higher on 107 days (43%). Its best day was October 16, 2026 (+34.31%) and its worst was June 26, 2026 (-21.30%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 3 times.
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for...
Find more stocks like CTSO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.